Cardiotoxicity of Contemporary Anticancer Immunotherapy.
CAR T cell therapy
COVID-19
Cardio-oncology
Cardiomyopathy
Cardiotoxicity
Chimeric antigen receptor
Cytokine release syndrome
ICI
Immune checkpoint inhibitor
Immunotherapy
Myocarditis
Journal
Current treatment options in cardiovascular medicine
ISSN: 1092-8464
Titre abrégé: Curr Treat Options Cardiovasc Med
Pays: United States
ID NLM: 9815942
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
05
10
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
ppublish
Résumé
Contemporary anticancer immunotherapy, particularly immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell therapy, has changed the landscape of treatment for patients with a variety of malignancies who historically had a poor prognosis. However, both immune checkpoint inhibitors and CAR T cell therapy are associated with serious cardiovascular adverse effects. As immunotherapy evolves to include high-risk patients with preexisting cardiovascular risk factors and disease, the risk and relevance of its associated cardiotoxicity will be even higher. ICI can cause myocarditis, which usually occurs early after initiation, can be fulminant, and prompt treatment with high-dose corticosteroids is crucial. CAR T cell therapy frequently leads to cytokine release syndrome, which is associated with cardiomyopathy or arrhythmia development and may also result in circulatory collapse. Supportive treatment, as well as tocilizumab, an anti-interleukin-6 receptor antibody, is the cornerstone of treatment. Recent findings suggest that preexisting cardiovascular risk factors and disease may increase the risk of such cardiotoxicity, and prompt recognition, as well as treatment, may favorably alter the outcomes. ICI and CAR T cell therapy have improved cancer-related outcomes; however, they both are associated with potentially therapy-limiting cardiotoxicity. Cardio-oncologists are required to play an important role in patient selection, pretherapy cardiovascular optimization, and prompt recognition and treatment of cardiotoxicity.
Identifiants
pubmed: 33162729
doi: 10.1007/s11936-020-00867-1
pii: 867
pmc: PMC7605901
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
62Informations de copyright
© Springer Science+Business Media, LLC, part of Springer Nature 2020.
Déclaration de conflit d'intérêts
Conflict of interestNatalie Dal’bo, Rushin Patel, Rohan Parikh, Sachin P. Shah, Avirup Guha, Sourbha S. Dani, and Sarju Ganatra declare that they have no conflict of interest.
Références
Circulation. 2007 Oct 30;116(18):2062-71
pubmed: 17938288
Ann Intern Med. 2003 May 20;138(10):807-11
pubmed: 12755552
J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108
pubmed: 31856966
Biol Blood Marrow Transplant. 2018 Aug;24(8):1590-1595
pubmed: 29772353
N Engl J Med. 2019 Jun 13;380(24):2375-2376
pubmed: 31189042
J Immunother Cancer. 2019 Feb 22;7(1):53
pubmed: 30795818
J Am Coll Cardiol. 2020 Feb 11;75(5):467-478
pubmed: 32029128
CA Cancer J Clin. 2020 Nov;70(6):480-504
pubmed: 32910493
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
Circulation. 2020 Oct 27;142(17):1687-1690
pubmed: 33104402
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
JACC CardioOncol. 2020 Jun;2(2):193-203
pubmed: 32776016
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219
J Am Coll Cardiol. 2019 Dec 24;74(25):3153-3163
pubmed: 31856973
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Nat Rev Immunol. 2018 Oct;18(10):605-616
pubmed: 30046149
Ther Clin Risk Manag. 2019 Feb 28;15:323-335
pubmed: 30880998
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Nat Med. 2003 Dec;9(12):1477-83
pubmed: 14595408
Oncologist. 2018 Aug;23(8):936-942
pubmed: 29567824
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Ann Oncol. 2018 Jan 1;29(1):250-255
pubmed: 29045547
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
Herz. 2000 May;25(3):200-9
pubmed: 10904839
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Lancet. 2004 Jan 17;363(9404):203-9
pubmed: 14738793
Circulation. 2020 Jun 16;141(24):2031-2034
pubmed: 32539614
JACC CardioOncol. 2020 Jun;2(2):350-355
pubmed: 32292919
N Engl J Med. 2019 Jun 13;380(24):2377-2379
pubmed: 31189043
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Cardiol Clin. 2019 Nov;37(4):385-397
pubmed: 31587780
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
J Natl Compr Canc Netw. 2020 Nov 3;:1-10
pubmed: 33142266
Eur Heart J. 2020 May 7;41(18):1733-1743
pubmed: 32112560
J Immunother Cancer. 2018 May 22;6(1):40
pubmed: 29789020
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Trends Cardiovasc Med. 2020 Aug;30(6):315-325
pubmed: 32474135
Circ Res. 2007 Aug 3;101(3):248-57
pubmed: 17569889
Mayo Clin Proc. 1989 Oct;64(10):1235-45
pubmed: 2593714